Quick Answer
NewAmsterdam Pharma Co N.V. reported Total Revenue of $22.50 million for the year ending 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -50.6% in Total Revenue from 2024 to 2025.
- This data is from NewAmsterdam Pharma Co N.V.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $8.63 million | Q2 2023: $1.72 million | Q3 2023: $2.94 million | Q1 2024: $1.40 million | Q2 2024: $2.28 million | Q3 2024: $29.11 million | Q1 2025: $2.98 million | Q2 2025: $19.15 million | Q3 2025: $348.0 thousand.
- Over the full 4 years of available data (2022 to 2025), NewAmsterdam Pharma Co N.V.'s Total Revenue has declined by 78.1%.
- Historical annual values: Fiscal year 2025: $22.50 million | Fiscal year 2024: $45.56 million | Fiscal year 2023: $14.09 million | Fiscal year 2022: $102.69 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: